As senior South Korean and U.S. officials prepare to reconvene in Washington, the Korean government’s quiet decision to shelve the Platform Monopoly Act while fast-tracking the Online Platform Fairness Act sends a troubling signal. Though framed as a more balanced alternative, the Fairness Act potentially represents another form of non-tariff attack on U.S. tech firms, posing an even greater threat to innovation, legal certainty, and the broader U.S.–Korea economic relationship.

President Trump has rightly emphasized that AI should be allowed to learn like humans do, and unless the UK adopts a commonsense approach to AI training and copyright, it risks falling behind China in the global AI race.

Fellow advocates of industrial policy, join me in being outspoken. You have nothing to lose but your intellectual chains and U.S. techno-economic survival to gain.

Over the last year, Missouri has seen a 200 percent increase in the number of broadband crimes.

The Trump administration should maintain export controls where they clearly advance national security. But it should also ensure that U.S. companies can compete globally, reinvest in innovation, and remain central to the technologies that will shape the future.

Korea’s highly educated workforce is increasingly stuck in low-quality jobs. This is not due to a lack of skill, but rather to government policies that penalize growth and fragment markets. Korea must embrace size neutrality, reforming regulations and incentives to support firms that innovate, scale, and compete globally.

What’s more likely to boost growth and tech leadership: a targeted innovation strategy for robotics or one focused on cleaner oceans? Just asking.

The Trump administration should push back against foreign governments enacting policies specifically tailored to undermine American tech companies and US leadership.

There are two core reasons for manufacturing decline denialism: fear of protectionism and blind faith in market forces.

The last three administrations have mandated updates and improvements to reduce unjustified regulatory burdens on biotech innovations, but only small steps have been taken where large ones are required, and the present turmoil threatens to impede improvements.